This extends the reach of CAR-T beyond TCR-restricted MHC-peptide targets as CAR-T cells have the ability to recognize tumor cell surface antigens without the MHC complex, allowing them to recognize a wide variety of targets on tumor cells without being affected by the loss of MHC expression. Here, HLA-C is linked to neoplasm.